Limertinib plus radiation for EGFR-mutant lung cancer with brain metastases
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a targeted pill (Limertinib) combined with radiation therapy for people with a specific type of lung cancer (EGFR mutation) that has spread to the brain. The goal is to see if this combination shrinks brain tumors and keeps them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that has spread to the brain (at least 3 brain lesions, one 2 cm or bigger).
- Your lung cancer has an EGFR mutation called 19Del or 21L858R, confirmed by a biopsy or blood test.
- You are 18 to 75 years old and your overall health is good enough for daily activities (ECOG 0 or 1).
- You have not had any previous cancer treatment for advanced lung cancer (like chemo, targeted therapy, or immunotherapy).
- Your kidneys, liver, and blood counts are within safe ranges, and you have no major heart or lung conditions.
- You agree to use effective birth control during the study and for 12 months after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
This trial tests combining a targeted pill (firmonertinib) with medication injected into the fluid around the spine for people with a specific type of lung cancer that has spread to the lining of the brain. It may offer a new option if you have already tried other EGFR drugs and are still having progression.
This trial tests whether adding chemotherapy and an immunotherapy drug (sintilimab) to targeted therapy (limertinib) before surgery works better than continuing targeted therapy alone. It is for people with stage II-IIIB EGFR-mutant lung cancer that can be removed with surgery.
This trial tests if adding an injected chemotherapy drug (pemetrexed) to a targeted oral pill (like osimertinib) works better than the pill alone for patients with lung cancer that has spread to the brain and spinal cord lining.
This trial tests a higher dose of the targeted pill firmonertinib combined with two other drugs (bevacizumab and pemetrexed) given into the spine for people with EGFR-mutant lung cancer that has spread to the lining of the brain. It aims to see if this combination can shrink or control the cancer in the central nervous system.
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.